S.2 Ep. 16 | Beyond the Headlines

Beyond the Headlines Series: PMDD and Antihistamines, Real-Time FDA Study Monitoring Using Al, and More!
Beyond the Headlines Series: PMDD and Antihistamines, Real-Time FDA Study Monitoring Using Al, and More!

Streaming now on: Amazon Music  |  Apple Podcasts  |  Spotify  |  Soundcloud  |  YouTube

Learn More About Beyond the Endpoint  |  View All Episodes

Hosts Manesh Patel and Emily O’Brien close out Season 2 of Beyond the Endpoint by examining a fresh set of health and science stories making waves in the news. The duo kicks off by assessing the FDA's ambitious new initiative to use real-time data to speed up clinical trials, weighing its promise against the practical challenges of implementation. They then turn to a recent executive order designating psychedelic research a federal priority, exploring what accelerated access could mean for patients with PTSD, severe depression, and addiction. Next, Patel breaks down recent advances in CAR T-cell therapy and how combining viral gene delivery with CRISPR editing may one day make this transformative approach accessible to patients with autoimmune conditions. Finally, O'Brien examines the viral social media claim that antihistamines can treat premenstrual dysphoric disorder.

Related Headlines from this Episode

Share